Development, calibration, and external validation of a semi-Markov model for hypertension in older adults with Medicare coverage in the United States
Authors:
Preprint
Abstract
Objective: To develop a semi-Markov model of hypertension specifically using estimates from primary analysis of Medicare data, and calibrate and validate using external trial and observational data. Methods: A semi-Markov model of hypertension with ten disease states was developed using clinical expertise and literature review: hypertension, myocardial infarction (MI), congestive heart failure (CHF), stroke, transient ischemic attack (TIA), other cardiovascular disease (CVD), chronic CVD, early-stage chronic kidney disease (ES CKD), late-stage CKD (LS CKD), and death. Most transition probabilities and hazard ratios for excess mortality were obtained from analysis of Medicare data (2018–2021). Transition probabilities and hazard ratios were calibrated against findings from the Systolic Hypertension in the Elderly Program (SHEP) trial and post-trial follow-up studies. Iterative grid search using Latin Hypercube Sampling was used for calibration, followed by a recalibration using Nelder-Mead simplex method with common random numbers. External validation was performed using mortality data after MI and stroke. Results: Final monthly transition probabilities from hypertension to other states were: other CVD (0.026), ES CKD (0.010), CHF (0.004), stroke (0.004), TIA (0.002), and MI (0.002). Final hazard ratios were: MI (3.29), CHF (3.99), stroke (3.79), TIA (1.39), other CVD (3.84), chronic CVD (1.39), ES CKD (1.24), and LS CKD (4.16). In the external validation, mortality rates per 100 person-years among stroke survivors were 7.8 (modeled) and 8.2 (observed). Conclusion: Our model was reasonably calibrated except for CHF incidence and stroke-related mortality. External validation showed the model performed well over longer timeframe, but discrepancies were observed for shorter periods.Keywords
This publication has 43 references indexed in Scilit:
- An Alternative Measure of Health for Value Assessment: The Equal Value Life-YearPharmacoEconomics, 2023
- Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure ControlJAMA Cardiology, 2022
- Trends in Remote Patient Monitoring Use in Traditional MedicareJAMA Internal Medicine, 2022
- Remote Patient Monitoring During COVID-19JAMA, 2022
- Trends in Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the USJAMA Internal Medicine, 2021
- Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular DiseasesApplied Health Economics and Health Policy, 2013
- Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term SurvivalJAMA, 2011
- Keeping the noise down: common random numbers for disease simulation modelingHealth Care Management Science, 2008
- Effect of Treating Isolated Systolic Hypertension on the Risk of Developing Various Types and Subtypes of StrokeThe Systolic Hypertension in the Elderly Program (SHEP)JAMA, 2000
- Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic HypertensionJAMA, 1991